Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

The accuracy of skin cancer diagnosis varied by lesion type, physician specialty and experience, and examination method, with ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Published ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.